Elliott Aaron Matthew
Known title: Chief Executive OfficerCIK: 0002144747
Associated companies
Transaction History
| FRNM | ▼ Sell | Tax Withholding | 71,920 | $1.1M | 9/2/2026 | View on chart |
| FRNM | ▼ Sell | Tax Withholding | 71,920 | $1.1M | 9/2/2026 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Freenome highlights CRC screening market potential
Freenome is emphasizing the large addressable market for its colorectal cancer screening test, noting it can reach 50 million patients while facing less direct competition. This narrative aims to support the company's growth outlook as the stock trades near its 52-week high range.
Freenome highlights CRC screening market potential. Freenome is emphasizing the large addressable market for its colorectal cancer screening test, noting it can reach 50 million patients while facing less direct competition. This narrative aims to support the company's growth outlook as the stock trades near its 52-week high range.